BidaskClub downgraded shares of Juno Therapeutics (NASDAQ:JUNO) from a buy rating to a hold rating in a research note published on Tuesday morning.
A number of other research analysts have also recently issued reports on the company. Zacks Investment Research raised Juno Therapeutics from a sell rating to a hold rating in a report on Wednesday, February 21st. Standpoint Research reissued a hold rating on shares of Juno Therapeutics in a report on Wednesday, January 24th. Barclays cut Juno Therapeutics from an overweight rating to an equal weight rating and lifted their price objective for the company from $55.00 to $87.00 in a report on Wednesday, January 24th. Leerink Swann cut Juno Therapeutics from an outperform rating to a market perform rating and lifted their price objective for the company from $56.00 to $87.00 in a report on Tuesday, January 23rd. Finally, Raymond James Financial cut Juno Therapeutics from an outperform rating to a hold rating in a report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $51.20.
Juno Therapeutics (JUNO) opened at $86.63 on Tuesday. The stock has a market capitalization of $9,890.00, a price-to-earnings ratio of -25.55 and a beta of 3.42. Juno Therapeutics has a twelve month low of $19.62 and a twelve month high of $86.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77.
A number of large investors have recently made changes to their positions in the business. Capital International Investors bought a new stake in Juno Therapeutics during the 3rd quarter worth about $256,339,000. BlackRock Inc. raised its holdings in Juno Therapeutics by 6.6% during the 4th quarter. BlackRock Inc. now owns 4,834,370 shares of the biopharmaceutical company’s stock worth $220,981,000 after purchasing an additional 299,586 shares during the last quarter. Orbimed Advisors LLC raised its holdings in Juno Therapeutics by 123.1% during the 3rd quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after purchasing an additional 1,126,400 shares during the last quarter. Jennison Associates LLC raised its holdings in Juno Therapeutics by 162.0% during the 3rd quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after purchasing an additional 1,229,622 shares during the last quarter. Finally, Capital Guardian Trust Co. bought a new stake in Juno Therapeutics during the 3rd quarter worth about $37,400,000. 71.49% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3227280/bidaskclub-downgrades-juno-therapeutics-juno-to-hold.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.